Lantern Pharma Inc.

NASDAQ:LTRN

Biotechnology

Healthcare
$3.93 -4.67%

-$0.19 today

Market cap
$50.14M
Beta
2.32
P/E (TTM)
-2.7
EPS (TTM)
-$1.41
52W Low $1.11High $5.74

Volume 0.10M

Average 0.68M

LTRN Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Lantern Pharma Inc.NASDAQ: LTRN

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$4.86M, compared with -$6.18M a year earlier.

Context

  • Net debt amounted to 67.3% of total assets at the end of Q1 FY2026, up 38.0 pp from a year earlier.
  • Net debt grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +21.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.86M+99.9% QoQ
Last fiscal yearDec 2025
-$4.34B-59677.7% YoY
Year agoMar 2025
-$6.18M+21.4% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.4%——
1 year-59677.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(4.34B) USD
Year-over-year change
-59677.7%

Net Debt vs competitors

How LTRN compares with its peers on the latest reported figures

  • LTRN's Mar 2026 net debt of -$4.86M is the highest of the 5 companies compared; the peer median is -$24.32M.
  • Its year-over-year change of +21.4% is the 3rd highest of 5, against a peer median of +25.5%.
  • Net debt amounts to 67.3% of total assets for LTRN, versus a peer median of 87.5%.
LTRN Competitors Peer median
Net Debt for LTRN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LTRNLantern Pharma Inc.Mar 2026-$4.86M +21.4%—67.3%
RNXTRenovoRx, Inc.Mar 2026-$12.18M +14.8%—87.2%
ANVSAnnovis Bio, Inc.Mar 2026-$14.22M +36.1%—87.5%
MAIAMAIA Biotechnology, Inc.Mar 2026-$34.41M -216.8%—97.4%
ATNMActinium Pharmaceuticals, Inc.Jun 2026-$35.13M +40.1%—87.5%
Peer median (excluding LTRN) -$24.32M+25.5%—87.5%

Competitors are the stored peer set for LTRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents51.52M37.2M21.94M7.51M4.42B
Short-term Investments19.2M17.99M19.36M16.5M5.7B
Net Receivables181K0860K00
Inventory00000
Other Current Assets378.95K541.18K745.65K1.23M683.95M
Total Current Assets72.72M58.72M43.34M25.25M10.8B
Property, Plant & Equipment (Net)216.19K95.7K280.42K287.43K107.47M
Goodwill00000
Intangible Assets00000
Long-term Investments1M0000
Tax Assets00000
Other Non-current Assets17.89K17.89K25.87K36.74K125.17M
Total Non-current Assets1.23M113.58K306.29K324.16K232.64M
Total Assets73.95M58.84M43.65M25.57M11.04B
Account Payables2.17M0942.21K00
Short-term Debt152.06K00078.54M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities02.75M1.56M4.14M4.42B
Total Current Liabilities2.33M2.8M2.68M4.33M4.5B
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities52.89K061.5K52.84K0
Total Liabilities2.38M2.8M2.74M4.38M4.5B
Common Stock1.11K1.09K1.07K1.08K1.13M
Retained Earnings(25.02M)(39.28M)(55.24M)(76.03M)(93.15B)
Accumulated OCI(92.69K)(371.39K)(107.46K)153.99K25.43M
Other Stockholders Equity000099.65B
Minority Interest00000
Total Equity71.57M56.04M40.91M21.19M6.53B
Total Debt204.95K52.89K234.47K243.66K78.54M
Net Debt(51.32M)(37.15M)(21.7M)(7.27M)(4.34B)

Lantern Pharma Inc.

NASDAQ:LTRN

Intrinsic Alpha fair value

Locked

Current Price

$3.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.